NasdaqGM - Delayed Quote • USD
Castle Biosciences, Inc. (CSTL)
At close: 4:00 PM EDT
After hours: 4:02 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 9 | 9 |
| Avg. Estimate | -0.33 | -0.68 | -2.24 | -1.95 |
| Low Estimate | -0.57 | -0.83 | -2.79 | -2.78 |
| High Estimate | -0.17 | -0.45 | -1.8 | -1.08 |
| Year Ago EPS | -1.1 | -0.7 | -2.14 | -2.24 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 9 | 9 |
| Avg. Estimate | 66.2M | 55.21M | 237.64M | 257.32M |
| Low Estimate | 55.4M | 53.2M | 235.4M | 247M |
| High Estimate | 69.75M | 59.2M | 240M | 265M |
| Year Ago Sales | 42.04M | -- | 219.79M | 237.64M |
| Sales Growth (year/est) | 57.50% | -- | 8.10% | 8.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.89 | -0.91 | -0.76 | -0.54 |
| EPS Actual | -1.1 | -0.7 | -0.26 | -0.1 |
| Difference | -0.21 | 0.21 | 0.5 | 0.44 |
| Surprise % | -23.60% | 23.10% | 65.80% | 81.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.33 | -0.68 | -2.24 | -1.95 |
| 7 Days Ago | -0.33 | -0.68 | -2.24 | -1.95 |
| 30 Days Ago | -0.32 | -0.65 | -2.14 | -1.89 |
| 60 Days Ago | -0.85 | -0.75 | -2.88 | -1.86 |
| 90 Days Ago | -0.85 | -0.76 | -2.89 | -1.89 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | CSTL | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 70.00% | -- | -- | 1.50% |
| Next Qtr. | 2.90% | -- | -- | 11.40% |
| Current Year | -4.70% | -- | -- | 5.20% |
| Next Year | 12.90% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Keybanc: Overweight to Overweight | 3/1/2024 |
| Maintains | Scotiabank: Sector Outperform to Sector Outperform | 3/1/2024 |
| Initiated | Guggenheim: Buy | 12/14/2023 |
| Maintains | Keybanc: Overweight to Overweight | 8/4/2023 |
| Reiterates | Lake Street: Buy to Buy | 7/7/2023 |
| Reiterates | Stephens & Co.: Overweight to Overweight | 7/6/2023 |
Related Tickers
BDSX Biodesix, Inc.
1.2600
-1.56%
ECX.F EPIGENOMICS AG NA O.N.
1.5150
+0.33%
BCART.BR Biocartis Group NV
0.2900
0.00%
DMTK DermTech, Inc.
0.6140
-0.32%
CDNA CareDx, Inc
7.98
-3.04%
FLGT Fulgent Genetics, Inc.
20.74
+0.48%
BNR Burning Rock Biotech Limited
0.8208
-5.29%
CNTG Centogene N.V.
0.4610
-3.96%
ENZ Enzo Biochem, Inc.
1.0600
-2.75%
GH Guardant Health, Inc.
18.10
+4.38%